A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2010
At a glance
- Drugs AMG 167; AMG 167
- Indications Metabolic bone diseases; Osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 06 Mar 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.
- 06 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.